Valemetostat
- Generic Name
- Valemetostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34ClN3O4
- CAS Number
- 1809336-39-7
- Unique Ingredient Identifier
- 60RD0234VE
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Valemetostat Tosylate (DS-3201b) with Atezolizumab and Bevacizumab in HCC
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 45
- Registration Number
- NCT06294548
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT05879484
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05683171
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT05633979
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
Phase 1
Recruiting
- Conditions
- Castration-Resistant Prostate CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Prostate CarcinomaMetastatic Urothelial CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Aggressive Variant Prostate CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT04388852
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 438
- Registration Number
- NCT03930953
- Locations
- 🇨🇱
Pontificia Universidad Catolica de Chile-Hemato-Oncology, Santiago, Metropolitana, Chile
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇺🇸Mayo Clinic Arizona - Scottsdale, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath